Natco Pharma FY26 Performance and Strategic Restructuring

Revenue stood at Rs 4,375.9 crore and Profit After Tax (PAT) reached Rs 1,418.5 crore for FY26.

Reader Takeaway: Crop Health demerger aims to unlock value while international expansion seeks to counter domestic pricing pressures.

What just happened

Natco Pharma has released its FY26 Annual Report, confirming a year of financial consolidation. The company reported a decline in consolidated revenue from Rs 4,784 crore in FY25 to Rs 4,375.9 crore. PAT also saw a contraction, moving from Rs 1,885.4 crore in the previous fiscal to Rs 1,418.5 crore. Despite the financial dip, the board has approved the demerger of the Crop Health Sciences business, set for October 2026, to allow the pharmaceutical arm to operate with a sharper strategic focus.

Why this matters

The demerger is a major structural shift. By hiving off the Crop Health Sciences division, management intends to create an independent growth trajectory for its pharmaceutical core. Furthermore, increasing the stake in Adcock Ingram Holdings (South Africa) to 49% signals an aggressive effort to diversify revenue streams away from domestic market dependence.

Risks to watch

Investors should monitor the impact of R&D and compliance costs, which continue to weigh on margins. Additionally, the company’s oncology portfolio remains susceptible to domestic pricing pressures, which contributed to the overall moderation in performance this year.

What to track next

Management has issued guidance projecting double-digit earnings growth over the next two to three years. Key drivers for this outlook include scaling international operations in Brazil, Canada, and South Africa. The success of the Crop Health Sciences demerger and the integration of the South African stake will be the primary benchmarks for shareholder value creation in the coming quarters.